Ability Pharmaceuticals SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.abilitypharma.com
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Ability Pharmaceuticals SL
- Target Recruit Count
- 150
- Registration Number
- NCT04431258
- Locations
- 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇪🇸ICO Badalona, Badalona, Barcelona, Spain
A Study of ABTL0812 in Pancreatic Cancer
Phase 1
Suspended
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Ability Pharmaceuticals SL
- Target Recruit Count
- 60
- Registration Number
- NCT03417921
- Locations
- 🇪🇸
Marc Cortal, Barcelona, Spain
A Study to Assess the Efficacy and Safety of ABTL0812
Phase 1
Completed
- Conditions
- Endometrial CancerSquamous Non-Small Cell Lung Cancer
- Interventions
- Drug: ABTL0812 in combination with paclitaxel and carboplatin
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Ability Pharmaceuticals SL
- Target Recruit Count
- 103
- Registration Number
- NCT03366480
- Locations
- 🇪🇸
Abilitypharma, Barcelona, Spain
Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Ability Pharmaceuticals SL
- Target Recruit Count
- 27
- Registration Number
- NCT02201823
- Locations
- 🇪🇸
Hospital Clínic, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath